预约演示

更新于：2026-02-27

Oxybutynin Chloride

盐酸奥昔布宁

更新于：2026-02-27

概要

基本信息

简介奥昔布宁是FDA于1975年批准用于治疗膀胱过度活动的药物。该药物最初由杨森开发，作为乙酰胆碱的竞争性拮抗剂，作用于节后毒蕈碱受体，使膀胱平滑肌松弛。它是R-和S-异构体的外消旋混合物，抗毒蕈碱活性主要存在于Risomer中。

药物类型

小分子化药

别名

Aroxybutynin、oxybutynin、Oxybutynin (USAN/INN)

+ [42]

靶点

mAChRs

作用方式

拮抗剂

作用机制

mAChRs拮抗剂(毒蕈碱型乙酰胆碱受体家族拮抗剂)

治疗领域

皮肤和肌肉骨骼疾病泌尿生殖系统疾病神经系统疾病+ [1]

在研适应症

非在研适应症

原研机构

在研机构

Hisamitsu Pharmaceutical Co., Inc.Teva Pharmaceuticals Europe BV

+ [6]

非在研机构

Ortho-McNeil Pharmaceutical LLC

McNeil Consumer & Specialty Pharmaceuticals, Inc.

ALZA Corp.

+ [3]

权益机构

Daewoong Pharmaceutical Co., Ltd.

Actavis, Inc.

Antares Pharma, Inc.

最高研发阶段批准上市

首次获批日期

美国 (1975-07-16),

膀胱过度活动症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C22H32ClNO3

InChIKeySWIJYDAEGSIQPZ-UHFFFAOYSA-N

CAS号1508-65-2

关联

120

项与盐酸奥昔布宁相关的临床试验

NCT07391878

/ Not yet recruiting临床2期

Open-Label Study to Evaluate the Safety and Efficacy of Two Doses of TRG-200 KIT in Patients With Refractory Overactive Bladder (OAB) : A Pilot Study

This is an open-label, single-center pilot study designed to evaluate the safety, tolerability, and preliminary efficacy of TRG-200 KIT, an intravesical sustained-release oxybutynin formulation, in adult patients with refractory overactive bladder (OAB). The study includes an adaptive two-stage design with initial dose evaluation of two dose levels (150 mg and 300 mg oxybutynin) followed by expansion using the selected dose. TRG-200 KIT is administered via monthly intravesical instillation and aims to provide prolonged local bladder exposure while minimizing systemic absorption and anticholinergic adverse effects.

开始日期2026-02-15

申办/合作机构

Trigone Pharma Ltd.

NCT06966778

/ Not yet recruitingN/AIIT

A Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy of Oxybutynin Chloride Extended-Release Tablets to Improve Early Continence Recovery After Robotic Prostatectomy

The goal of this double-blind, randomized, placebo-controlled study is to evaluate whether oxybutynin chloride extended-release tablets can improve early continence recovery after robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer.
The main questions it aims to answer are:
[Does oxybutynin chloride improve continence recovery after RARP compared to a placebo?] [What are the predictors of continence recovery?]
Researchers will compare the treatment group (oxybutynin chloride 10 mg/day) with the control group (placebo) to assess differences in continence outcomes.
Participants will:
[Take the assigned medication (oxybutynin chloride or placebo) daily for 1-3 months until continence recovery.] [Complete surveys (e.g., IPSS, IIEF, ICIQ) at several time points post-surgery, including before surgery, 10 days after Foley catheter removal, and up to 12 months.] [Record any adverse events or concomitant medication use.]
Safety and tolerability will be monitored, and statistical analyses will determine the efficacy and predictors of continence. The study adheres to ethical principles, local regulations, and GCP guidelines.

开始日期2025-09-23

申办/合作机构

国立台湾大学医学院附设医院

[+1]

NCT07027020

/ Not yet recruiting临床3期IIT

Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial

Malformation of the lumbosacral region (spina bifida) affects the innervation of the bladder in children. The usual evolution leads to a neurological bladder with small capacity, poor compliancy and overactivity, exposing to incontinence and obstruction to the evacuation of urine. It is responsible for renal failure requiring dialysis and transplantation. Current therapeutics aim to evacuate urine and reduce intravesical pressure. It gradually combines 1) intermittent catheterization, 2) anticholinergics, 3) botulinum toxin (Botox®) injection into the detrusor (bladder muscle) by cystoscopy and 4) surgery (vesicostomy, Bricker, enterocystoplasty). Oxybutynin relaxes the detrusor, improves continence and reduces intravesical pressure. It is usually administered per os, but there are contraindications (glaucoma, myasthenia), side effects (constipation, dry mouth). It can be difficult to swallow for children, and drug resistance may develop. It can lead to ineffective treatment requiring therapeutic escalation. The next step, intradetrusor Botox® injection, is invasive (cystoscopy), has a limited duration of action (6 months) and must be performed under general anesthesia in children.
Surgical treatments are effective but irreversible and responsible for morbidity and mortality. A randomized study was performed demonstrating the efficacy of intravesical oxybutynin compared to oral administration in adult patients. This study found a significant increase in bladder capacity and a significant decrease in side effects in the intravesical oxybutynin group. Due to the relative difficulties of intravesical oxybutynin delivery (preparation, cost) and the more invasive nature, it is not used as an alternative to oral oxybutynin.
Our hypothesis is that this treatment may have a legitimate place in the treatment of neurogenic bladder in patients with failure of anticholinergic treatment before a therapeutic escalation requiring an invasive procedure (Botox®, enterocystoplasty) especially in children for whom repeated general anesthesia for Botox® injection may interfere with brain development. In this way, we aim to extend the time to therapeutic escalation in the pediatric population.
The main objective of the trial is to compare the efficacy on maximal bladder capacity of intravesical oxybutynin instillation versus placebo in the treatment of children with overactive neurogenic bladder (spina bifida), performing intermittent catheterization, for whom oral anticholinergic treatment is ineffective or poorly tolerated.

开始日期2025-09-01

申办/合作机构

FARCO-PHARMA GmbH

100 项与盐酸奥昔布宁相关的临床结果

登录后查看更多信息

100 项与盐酸奥昔布宁相关的转化医学

登录后查看更多信息

100 项与盐酸奥昔布宁相关的专利（医药）

登录后查看更多信息

1,771

项与盐酸奥昔布宁相关的文献（医药）

2026-02-01·BJU INTERNATIONAL

Article

作者: Epstein, Jonathan ; Hatem, Zahi ; Buzzi, Marie ; Lemelle, Jean‐Louis ; Mazeaud, Charles ; Juge, Nadine ; Berte, Nicolas

Background:

Neurogenic bladder is defined as a dysfunction of the bladder resulting from damage to the central or peripheral nervous systems. Its treatment is based on a progressive therapeutic escalation, rapidly involving invasive therapeutic procedures such as repeated intradetrusor injections and surgery. Given the risk of repeated general anaesthesia in children, there is a need for non‐invasive treatment for young patients who do not respond to or have adverse effects from oral anticholinergic treatment. The ‘Place de l’OXybutynine Intravésicale chez le Patient Enfant Neurologique’ (POXIPEN) trial aims to assess the efficacy of intra‐vesical oxybutynin on bladder capacity in a sample of French children with neurogenic bladder.

Study Design:

The POXIPEN is a multicentre, randomised, double‐blind, placebo‐controlled trial.

Endpoints:

The primary outcome is change in maximal bladder capacity after treatment. Secondary outcomes include changes in voiding, urodynamic and ultrasound parameters. We will also assess changes on quality of life and usability of the product.

Patients and Methods:

We aim to randomly assign 60 children with neurogenic bladder secondary to spina bifida and deemed non‐responders to first‐line treatment with oral anticholinergics, to receive intravesical oxybutynin (IVO) or placebo for 4 weeks. Recruitment will start in September 2025. It will be the first prospective study to evaluate the efficacy of IVO in children, with a high level of evidence provided by its design. If IVO proves effective, it could lengthen the delay in therapeutic escalation to invasive procedures, thereby reducing the risk of complications associated with general anaesthesia in children with neurogenic bladder.

Trial registration:

This trial is registered with the European Union (EU) Clinical Trials Information System (CTIS) under EU CT Number: 2022–501 902–36‐00 (approved 09.01.2025) and ClinicalTrials.gov under identifier NCT07027020 (registered 18.06.2025).

2026-02-01·Journal of Pediatric Urology

Early findings on OnabotulinumtoxinA for postoperative pain control in bladder exstrophy

Article

作者: Robey, Catherine ; Vecchione, Tricia ; Gearhart, John P ; George, Jessica ; Hunsberger, Joann ; Heap, David ; Yang, Jason ; Crigger, Chad B ; Maxon, Victoria ; Di Carlo, Heather N

INTRODUCTION:

Postoperative pain management in bladder reconstruction and exstrophy closure is challenging due to unique physiological differences in exstrophy patients, surgical complexity, and heightened risk of painful bladder spasms. While opioids and anticholinergics are used for pain relief, their prolonged use is associated with complications.

OBJECTIVE:

We sought to evaluate postoperative benefits of OnabotulinumtoxinA (Botox) injections in patients with classic bladder exstrophy (CBE) and cloacal exstrophy (CE) undergoing bladder reconstruction or exstrophy closure.

STUDY DESIGN:

CBE and CE patients who underwent bladder reconstruction or exstrophy closure between 2018 and 2024 were identified from an institutional database. Bladder reconstruction was defined as any combination of the following procedures - bladder neck reconstruction, bladder neck transection, Mitrofanoff or Monti catheterizable channel creation, and bladder augmentation. Reconstructive patients were stratified by concurrent ureteral reimplants necessitating ureteral stent placement. Data on postoperative course, medications, and complications were collected.

RESULTS:

Among 48 patients undergoing bladder reconstruction, 14 received Botox and 34 did not. Of the 34 exstrophy closures, 12 received Botox and 22 did not. In patients undergoing bladder reconstruction without ureteral reimplants necessitating ureteral stents, Botox significantly reduced oxybutynin use (0.09 mg/kg/day vs. 0.15 mg/kg/day, p = 0.02) and oxycodone use (0.00 mg/kg/day vs. 0.11 mg/kg/day, p = 0.03). These patients also experienced fewer days with pain scores above 0 (4.00 days vs. 10.00 days, p = 0.04) and above 4 (2.00 days vs. 6.00 days, p = 0.04). In contrast, bladder reconstruction patients with ureteral reimplantation necessitating ureteral stents showed no significant differences in medication use or pain scores (all p > 0.05). Botox did not significantly impact postoperative course, medication requirements, in exstrophy closures (all p > 0.05).

DISCUSSION:

Botox injections significantly improved postoperative outcomes and reduced medication use in exstrophy patients undergoing bladder reconstruction without ureteral reimplantation that necessitate ureteral stent placement. However, there was no statistical significance noted in the intervention group compared to controls in cases involving ureteral reimplantation with stent placement. Furthermore, Botox showed no postoperative advantages in exstrophy closure, where surgical complexity may limit its therapeutic efficacy. Limitations include the retrospective design and small sample size.

CONCLUSIONS:

Intraoperative Botox reduced opioid and anticholinergic use, as well as postoperative pain, among exstrophy patients undergoing bladder reconstruction without ureteral reimplants requiring ureteral stents. This demonstrates its potential as an effective adjunct for postoperative pain in exstrophy patients undergoing select reconstruction.

2026-02-01·JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Biologic therapy plus oral oxybutynin chloride in hidradenitis suppurativa: A potentially valid therapy to moderate acute flares

Article

作者: Candelora, Matteo ; Lucarini, Guendalina ; Molinelli, Elisa ; Gambini, Daisy ; Dragonetti, Maria L ; Richiardi, Irene ; Belleggia, Sara ; De Simoni, Edoardo ; Offidani, Annamaria ; Simonetti, Oriana

项与盐酸奥昔布宁相关的新闻（医药）

2026-02-10

·医药企业项目管理大会

候选药物发展资讯（一）

会议推荐 2026第三届中国医药企业项目管理大会 2026第二届中国AI项目管理大会 2026第十五届中国PMO大会 2026第五届中国项目经理大会本文目录 1、ACS Fall 2025 12个最新公布的临床候选药物 2、新药研发第2期:10个热门候选药物进入关键临床阶段 3、全球新药管线第6期:多款候选药物挺进Ⅲ期，临床迎来新突破 4、Sci Adv | 中国药科大学筛选到具有双重抗衰老和抗阿尔茨海默病疗效的候选药物一、ACS Fall 2025 12个最新公布的临床候选药物（原创 DrugOne DrugOne） 1 BMS-986470（Bristol Myers Squibb） Ph-1 | 双靶点 ZBTB7A/WIZ 分子胶降解剂通过降解 ZBTB7A 与 WIZ 来诱导胎儿血红蛋白（HbF）表达。在镰状细胞病小鼠与非人灵长类模型中，HbF 诱导效果优于临床常用的羟基脲。 2 BMS-986463（Bristol Myers Squibb） Ph-1 | 首个 WEE1 分子胶降解剂基于 CELMoD™ 技术发现。在异种移植瘤模型中实现持续性 WEE1 降解并诱导显著肿瘤回缩。 3 PF-07899895（Pfizer） Ph-1 | 靶向结肠的泛 SIK 抑制剂（软药）用于治疗肠道炎症，局部活性强而系统暴露低。展现出良好的溶解度、渗透性和强效的前临床疗效。 4 PF-07293893（Pfizer） Ph-1 | AMPK γ3 激活剂面向心力衰竭治疗，通过片段基药物设计发现。已优化出良好的效力与 ADME 特性。 5 IID432（Novartis） Ph-1 | 靶向克氏锥虫的拓扑异构酶 II 抑制剂基于氰基三唑骨架，对 T. cruzi 高选择性。在小鼠慢性查加斯病模型中，仅单剂量即实现彻底清除。 6 ETN029（Mariana Oncology / Novartis） Ph-1 | 宏环肽放射配体（DLL3 靶点）应用于小细胞肺癌与神经内分泌型前列腺癌。与 [177Lu] 和 [225Ac] 标记后，展现出高亲和结合、肿瘤滞留和强效疗效。 7 GS-1427（Gilead Sciences） Ph-2 | 口服 α4β7 整合素抑制剂高选择性，避免 α4β1 相关副作用。在炎症性肠病模型中疗效可比肩抗体药物。 8 AZD0233（AstraZeneca） Ph-1 | CX3CR1 拮抗剂针对 CX3CL1–CX3CR1 轴，应用于扩张型心肌病。 9 FOG-001（Parabilis Medicines） Ph-1/2 | 稳定化 α-螺旋肽（Helicon™ 技术）抑制 β-catenin/TCF4 相互作用，靶向 Wnt 通路。具皮摩尔级亲和力，可实现体内调控并支持每周给药。 10 TYRA-200（Tyra Biosciences） Ph-1 | 共价 FGFR2 抑制剂克服现有 FGFR 抑制剂耐药突变。在胆管癌及其他 FGFR2 突变驱动癌中实现显著肿瘤回缩。 11 MOMA-341（MOMA Therapeutics） Ph-1 | 共价 WRN 抑制剂靶向 Cys727，利用合成致死机制，适用于 MSI-H/dMMR 肿瘤。在异种移植瘤模型中展现强效肿瘤抑制。 12 LRK-4189（Larkspur Biosciences） Ph-1 | PIP4K2C 降解剂针对与结直肠癌不良预后相关的脂质激酶。在 MSS CRC 患者来源模型中显示约 50% 应答率，并触发免疫介导杀伤。总结分子胶与蛋白降解正在快速进入临床。肽类与宏环分子在放射配体和 PPI 靶向中展现潜力。耐药克服与新型作用机制成为焦点（如 FGFR2、WRN、PIP4K2C）。传染病与炎症疾病领域同样迎来小分子突破。整理 | DrugOne团队二、新药研发第2期:10个热门候选药物进入关键临床阶段（原创 Drughunter DrugFinder） JNJ-37822681 (D₂ receptor, Kv7 channel) D₂ 受体拮抗剂，Kv7 通道激活剂，JOHNSON & JOHNSON INNOVATIVE MEDICINE, BEERSE, BEII 期：精神分裂症快速导出的 D₂ 受体模拟化合物筛选，并优化以减轻 hERG/CYP2D6 抑制pizuglanstat (HPGDS) HPGDS 抑制剂，TAIHO PHARMACEUTICAL, TOKYO, JPIII 期：杜氏肌营养不良症命中化合物鉴定方法未披露VNT-101 (influenza NP:NP PPI) 流感 NP/NP 蛋白–蛋白相互作用抑制剂临床前：甲型流感病毒NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, EMERYVILLE, CAK-757 / K-833 (GPR40, GPR119) 肠道限制型 GPR40 激动剂（K-757）、GPR119 激动剂（K-833），KALLOYPE, NEW YORK, NYII 期：肥胖症文献起始点，骨架跃迁，并优化物化性质osivelotor (HbS) 血红蛋白 S 聚合抑制剂，GLOBAL BLOOD THERAPEUTICS, SAN FRANCISCO, CA / PFIZERIII 期：镰状细胞病基于 PK 和 OEC 指导的 SAR 优化 voxelotor 类似物SNT-5382 (LOXL2) LOXL2 抑制剂，SYNTARA, FRENCHS FOREST, AUI 期：心脏纤维化氟代胺–基骨架跃迁及非 CYP 代谢不稳定性优化compound 41 (14-3-3σ:ERα PPI) 14-3-3σ:ERα PPI 共价胶水稳定剂，UCSF, SAN FRANCISCO, CA / UNIVERSITY OF CRETE, HERAKLION, GR肿瘤学临床前来自先前 14-3-3σ:ERα 稳定剂的骨架跃迁；药效团虚拟筛选 ~31 万化合物alogabat (GABA-A alpha5 receptor) GABA-A α5 受体正向别构调节剂，ROCHE, BASEL, CHII 期：自闭症谱系障碍、安格尔曼综合征命中化合物鉴定方法未披露AD109 (muscarinic receptor, norepinephrine transporter) 毒蕈碱受体拮抗剂（aroxybutynin）、去甲肾上腺素再摄取抑制剂（atomoxetine），APNIMED, CAMBRIDGE, MAIII 期：阻塞性睡眠呼吸暂停命中化合物鉴定方法未披露obefazimod (miR-124) miR-124 增强剂，ABIVAX, PARIS, FRIII 期：溃疡性结肠炎、克罗恩病、COVID-19（已终止）来源于 ICiG 启发的 1,000 个化合物聚焦库筛选三、全球新药管线第6期:多款候选药物挺进Ⅲ期，临床迎来新突破（原创 Drugfinder DrugFinder）临床进展：10个候选分子中，3 个处于 III 期（Navacaprant、Iclepertin、Volasertib），显示出临床转化潜力强。热门靶点：靶点集中在信号通路调控与转录调节类（如 WEE1、STAT3、PLK1、CDK8/19），凸显抗肿瘤与神经疾病方向。研发主体：以跨国药企为主（如 Boehringer、GSK、Zentalis），但也有学术机构与创新生物科技公司参与（如 Baylor、Interdict）。早期研究：约 40% 分子仍处于临床前阶段，体现新靶点（如METTL3、Ribosome PTC）正加速探索。四、Sci Adv | 中国药科大学筛选到具有双重抗衰老和抗阿尔茨海默病疗效的候选药物（原创 Chronobiologists Chronobiology 时间生物学）图 1. AI 指导的重新用途识别出 MLT 用于治疗衰老和 AD，而 MLT 原本是用于治疗失眠的药物。对 161 份人体样本的临床分析显示，血清褪黑素 (MLT) 水平降低与衰老相关为了从临床角度验证 MLT 在衰老中的作用，对 161 份来自不同年龄段人群的临床血清样本进行了严格的横断面分析（图 2A）。考虑到检测血清中痕量 MLT 浓度的固有难度，采用了一种标准的液相色谱-串联质谱 (LC-MS/MS) 检测技术，并在多反应监测 (MRM) 模式下运行，以确保定量分析的准确性（图 2B）。定量分析结果显示，血清 MLT 水平与年龄呈显著负相关 (r = −0.289, P < 0.001)，表明血清 MLT 水平随年龄增长而逐渐降低（图 2C）。为了进一步验证这一关系，将受试者分为年轻组（<60岁）和老年组（≥60岁）。老年组的血清褪黑素（MLT）水平显著低于年轻组，有力地证实了MLT水平随年龄增长而降低（图2D）。这些来自大量队列的临床发现有力地表明，血清MLT浓度下降与衰老相关，提示血清MLT水平降低可能代表与衰老和神经退行性疾病易感性相关的关键风险因素或生物标志物。图 2. 对 161 个人类样本的临床分析显示，血清 MLT 水平降低与衰老相关。 MLT补充剂可减轻Aβ前体蛋白/早老素-1小鼠的认知障碍和AD病理特征为了验证MLT治疗AD的潜力，首先使用过表达瑞典突变型人Aβ前体蛋白（APPswe细胞）的人神经母细胞瘤SH-SY5Y细胞进行了体外实验。MLT显著下调了APP、细胞因子白细胞介素-1β（IL-1β）和单核细胞趋化蛋白1（MCP1）的表达（图3，A至C），表明其具有改善AD相关病理标志物和神经炎症反应的体外潜力。为了评估MLT在改善AD相关认知和记忆功能障碍方面的治疗效果，给6月龄的APP/早老素-1（PS1）AD模型小鼠服用含MLT的饮用水（图3D）。采用Morris水迷宫（MWM）分析来检测小鼠的空间学习和记忆能力。在MWM测试的训练阶段，与野生型（WT）小鼠相比，APP/PS1对照组小鼠在训练第5天寻找平台所花费的时间更长，而MLT治疗显著缩短了第4天和第5天的逃避潜伏期（图3E）。在测试阶段，与WT对照组相比，APP/PS1小鼠表现出空间导航能力受损，逃避潜伏期显著延长，到达平台的路径长度增加，表明其存在认知缺陷（图3F至H）。MLT治疗改善了所有这些行为指标，表明其对AD相关认知障碍具有治疗效果。图 3. MLT 补充剂可减轻体外和体内的认知障碍和 AD 的病理特征。 MLT通过调节衰老相关通路改善间充质干细胞的细胞衰老正如预期的那样，MLT处理显著减少了衰老相关β-半乳糖苷酶（SA-β-Gal）阳性细胞，并减弱了衰老MSCs中活性氧（ROS）的积累（图4A和4B）。MLT抑制了衰老细胞中SASP成分（MCP1、TNF和IL1A）的表达，同时上调了TGFβ的表达（图4C）。衰老的标志之一是线粒体功能障碍的发生 (37)。衰老间充质干细胞 (MSC) 的线粒体功能障碍表现为线粒体膜电位 (MMP) 降低，这可由 JC-1 单体（绿色）/聚集体（红色）荧光比值的升高来证实，而 MLT 处理可恢复这种比值（图 4D）。MLT 还减弱了 H2A 组蛋白家族成员 X (H2AX) 的磷酸化，这是衰老过程中 DNA 损伤应激的标志（图 4E）。值得注意的是，褪黑素（MLT）显著降低了衰老间充质干细胞（MSCs）中p21、p16和p53蛋白水平的升高，表明其潜在的抗衰老机制是通过调节衰老通路实现的（图4，F至H）。这些蛋白的上调导致Rb蛋白磷酸化不足，而这种与衰老相关的信号通路可被MLT的药理学干预显著逆转（图4I）。衰老细胞的有丝分裂阻滞导致核纤层蛋白Lamin B1表达的丧失。衰老MSCs表现出Lamin B1的显著下调，而MLT干预可使其恢复（图4J）。药理学上，MLT给药可改善衰老MSCs中与衰老相关的标志性改变。图 4. MLT 通过调节衰老相关通路改善 MSC 中的细胞衰老。图6. MLT通过调节p300/SP1相关超级增强子区域来调控BMAL1转录。图 7. BMAL1 是褪黑素介导的神经保护和抗衰老活性的中心效应因子。 end 本公众号声明： 1、如您转载本公众号原创内容必须注明出处。 2、本公众号转载的内容是出于传递更多信息之目的，若有来源标注错误或侵犯了您的合法权益，请作者或发布单位与我们联系，我们将及时进行修改或删除处理。 3、本公众号文中部分图片来源于网络，版权归原作者所有，如果侵犯到您的权益，请联系我们删除。 4、本公众号发布的所有内容，并不意味着本公众号赞同其观点或证实其描述。其原创性以及文中陈述文字和内容未经本公众号证实，对本文全部或者部分内容的真实性、完整性、及时性我们不作任何保证或承诺，请浏览者仅作参考，并请自行核实。

2026-02-10

·drugs

Oxybutynin Beats Placebo for Reducing ADT-Linked Hot Flashes in Prostate Cancer

TUESDAY, Feb. 10, 2026 -- For men with prostate cancer experiencing androgen deprivation therapy-associated hot flashes , oxybutynin is superior to placebo in improving symptoms, according to a study published online Jan. 26 in the Journal of Clinical Oncology . Bradley J. Stish, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined whether oxybutynin could improve hot flash symptoms in a study involving patients with prostate cancer receiving a stable regimen of androgen deprivation therapy with at least 28 hot flashes per week. Participants were randomly assigned to receive oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for six weeks; 81 participants were eligible for a final analysis, reporting an average of 10.1 hot flashes per day. The researchers found that patients in the placebo arm, 2.5-mg oxybutynin arm, and 5-mg oxybutynin arm had reductions in hot flashes/day of 2.15, 4.77, and 6.89, respectively, on average. The daily hot flash scores were reduced by an average of 4.85, 9.94, and 13.95 points, respectively, for placebo, 2.5 mg oxybutynin, and 5 mg oxybutynin. There were no treatment-related grade 3+ adverse events reported. The Hot Flash-Related Daily Interference Scale scores improved by 14.2 and 20.7 points in the 2.5-mg and 5-mg oxybutynin arms, respectively, and by 3.1 points in the placebo arm. "Oxybutynin demonstrated clear and clinically meaningful improvements in both hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer," Stish said in a statement. "These results provide strong support for its use as an effective management option for this challenging and often overlooked side effect of prostate cancer treatment." Several authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text (subscription or payment may be required)

临床结果

2026-02-04

·drugs

Oxybutynin Can Reduce Hot Flashes Among Prostate Cancer Patients

WEDNESDAY, Feb. 4, 2026 — A pill used to treat an overactive bladder can also be used to reduce hot flashes among men taking hormone-deprivation therapy for prostate cancer . Men taking oxybutynin had a dramatic decrease in the number and intensity of hot flashes that occurred as a result of their prostate cancer treatment, researchers reported Feb. 2 in the Journal of Clinical Oncology . “Oxybutynin demonstrated clear and clinically meaningful improvements in both hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer,” said lead researcher Dr. Bradley Stish , a radiation oncologist at the Mayo Clinic in Rochester, Minnesota. “These results provide strong support for its use as an effective management option for this challenging and often overlooked side effect of prostate cancer treatment,” Stish said in a news release. Hormone therapy is an effective treatment against prostate cancer, lowering levels of male hormones like testosterone that fuel cancer cells. However, the therapy causes hot flashes in up to 80% of men taking it, leading to fatigue and bad sleep, researchers said in background notes. These side effects often cause patients to stop taking their meds. Previous studies have shown that oxybutynin can significantly reduce hot flashes among women, so researchers figured the drug might have a similar effect among men. For the new study, researchers recruited 88 men with an average age of 68, and randomly assigned them to one of three groups. Two groups took either a high or low dose of oxybutynin daily, and the third took a placebo. Researchers found that men on the high dose of oxybutynin had the largest improvements, with nearly seven fewer hot flashes daily and a 14-point reduction in hot flash severity on a scale running from 0 to 100. By comparison, men on a placebo had two fewer hot flashes daily and a 5-point drop in hot flash severity, and men on the low dose of oxybutynin had nearly five fewer hot flashes daily and a 10-point drop in severity. Improvements also occurred quickly, often during a man’s first week taking the pill, researchers said. The share of patients who achieved at least a 50% reduction in their hot flash scores was also higher among oxybutynin patients — 79% in the high-dose group and 57% in the low-dose group, versus 32% taking a placebo. “These results are incredibly encouraging,” Stish said. “Men with hot flashes from hormone therapy now have another therapeutic option available to help reduce their symptom burden." He said future research will look to learn more about hot flash therapy options in these patients. Sources Alliance for Clinical Trials in Oncology, news release, Feb. 2, 2026

临床结果放射疗法

100 项与盐酸奥昔布宁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00722	盐酸奥昔布宁	G04BD04	DB01062

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
多汗症	澳大利亚	Accelagen	2025-09-12
掌跖多汗症	日本	Hisamitsu Pharmaceutical Co., Inc.	2013-03-27
尿频	日本	Clinigen KK	1988-03-29
尿失禁	日本	Clinigen KK	1988-03-29
尿急	日本	Clinigen KK	1988-03-29
脊柱裂	美国	Ortho-McNeil Pharmaceutical LLC	1979-11-29
急迫性尿失禁	美国	Ortho-McNeil Pharmaceutical LLC	1979-11-29
膀胱过度活动症	美国	Janssen Pharmaceuticals, Inc.	1975-07-16

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
下尿路症状	临床3期	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	2004-05-01
排尿障碍	临床3期	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	2004-05-01
压力性尿失禁	临床3期	-	ALZA Corp.	1995-12-01
糖尿病周围神经病变	临床前	美国	Eastern Virginia Medical School	2024-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT07027020 (POXIPEN, Pubmed \| BJU Int)	临床3期	-	60	Intravesical oxybutynin	範齋獵艱獵鏇蓋觸憲膚(窪鬱範範遞艱餘築衊艱) = 蓋蓋範廠襯構憲範鏇膚鹹構廠選鹹膚醖壓獵鏇 (艱鹽獵簾願觸廠願蓋顧 ) 更多	积极	2025-11-03
				Placebo	範齋獵艱獵鏇蓋觸憲膚(窪鬱範範遞艱餘築衊艱) = 鹹繭膚艱鏇餘願鏇夢願鹹構廠選鹹膚醖壓獵鏇 (艱鹽獵簾願觸廠願蓋顧 )
NCT04115878 (MOSAIC, CTgov)	临床2期	阻塞性睡眠呼吸暂停综合征 \| 唐氏综合征	22	oxybutynin+oxybutynin (ato-oxy)+ato-oxy (High Dose Ato-oxy)	願蓋繭蓋遞餘願餘範簾(襯壓鑰範窪餘製遞繭艱) = 鏇遞鏇鬱獵窪製醖醖餘顧鹹鹹蓋製膚築構醖淵 (膚蓋夢窪壓鬱糧蓋艱夢, 2.74) 更多	-	2025-08-19
				Atomoxetine and oxybutynin (ato-oxy) (Low Dose Ato-oxy)	願蓋繭蓋遞餘願餘範簾(襯壓鑰範窪餘製遞繭艱) = 淵廠築齋鏇網鑰鏇簾襯顧鹹鹹蓋製膚築構醖淵 (膚蓋夢窪壓鬱糧蓋艱夢, 3.06) 更多
NCT01370811 (CTgov)	临床2期	流涎 \| 帕金森病	24	OC (OC Oral Solution Treatment B)	壓製簾鏇鹽糧醖糧鑰窪(齋遞夢窪選壓憲糧鹹獵) = 繭鹽齋壓範築製築衊鬱網艱選鏇鏇築繭醖齋網 (觸網襯齋鹹齋簾遞築齋, 0.165) 更多	-	2023-04-10
				OC (OC Oral Solution Treatment C)	壓製簾鏇鹽糧醖糧鑰窪(齋遞夢窪選壓憲糧鹹獵) = 繭醖遞積憲壓鬱觸廠夢網艱選鏇鏇築繭醖齋網 (觸網襯齋鹹齋簾遞築齋, 0.147) 更多
NCT04090190 (CTgov)	临床4期	炎症 \| 急迫性尿失禁	20	Oxybutynin+Tolterodine+Trospium+Solifenacin+Fesoterodine	製遞範醖餘構構獵蓋糧(繭廠醖艱衊醖餘鏇構顧) = 範獵繭鹽築糧餘膚鏇製網襯築繭廠願壓艱積構 (膚獵鏇齋願衊夢觸蓋積, 築繭網鬱鏇鹹醖構觸鬱 ~ 選選餘壓糧築構鹽糧糧) 更多	-	2022-10-03
WSC2022	临床2期	阻塞性睡眠呼吸暂停综合征	30	Atomoxetine 75 mg + Aroxybutynin 2.5 mg	蓋構網遞窪壓艱繭選構(構顧壓鹽鹽艱觸夢網壓) = 簾鑰構窪窪選積醖壓顧範遞鑰醖壓簾鑰齋鏇艱 (繭顧艱繭夢鑰蓋鬱鹽鹹 ) 更多	积极	2022-03-11
				Atomoxetine 37.5 mg + Aroxybutynin 2.5 mg	蓋構網遞窪壓艱繭選構(構顧壓鹽鹽艱觸夢網壓) = 積鬱網觸願願醖壓壓鹽範遞鑰醖壓簾鑰齋鏇艱 (繭顧艱繭夢鑰蓋鬱鹽鹹 ) 更多
NCT04534491 (CTgov)	临床3期	膀胱过度活动症	855	Oxybutynin	襯獵繭顧糧鬱製蓋廠遞 = 衊願餘鏇願網糧簾鑰觸積觸構觸糧夢鑰淵獵艱 (構鑰獵範蓋醖齋鹽範顧, 憲製窪觸簾範網構網築 ~ 餘廠築築淵繭艱觸憲窪) 更多	-	2020-10-20
NCT02961790 (CTgov)	临床3期	潮热 \| 乳腺癌 \| 非浸润性导管内癌	150	Oxybutynin Chloride (High-dose Oxybutynin Chloride Group)	淵糧選衊壓獵製憲觸範(網窪願鏇構淵壓遞願繭) = 顧獵簾艱網齋鑰構觸選遞醖糧壓蓋夢製鹽夢網 (襯鹹淵夢繭廠遞鑰壓鏇, 15.6) 更多	-	2019-06-03
				Oxybutynin Chloride (Low-dose Oxybutynin Chloride Group)	淵糧選衊壓獵製憲觸範(網窪願鏇構淵壓遞願繭) = 製鑰餘齋齋鏇觸齋鏇獵遞醖糧壓蓋夢製鹽夢網 (襯鹹淵夢繭廠遞鑰壓鏇, 7.7) 更多
NCT02633371 (CTgov)	N/A	原发性腋窝多汗症	10	Oxybutynin 3% gel	鹽襯範觸齋廠蓋艱膚廠 = 憲鏇選鹽製齋遞膚艱積壓醖餘鑰繭觸鹽願獵鹹 (獵糧築築鏇鹽廠鑰廠憲, 選範淵簾獵憲鹽膚簾築 ~ 鏇膚壓選艱觸夢糧積憲) 更多	-	2018-06-19
NCT02176642 (APP, CTgov)	临床4期	急迫性尿失禁	55	Posterior Tibial Nerve Stimulation+Oxybutynin extended release (Oxybutynin Plus PTNS)	鑰壓築觸構蓋醖餘製鑰(衊鏇糧遞積獵構廠襯簾) = 蓋積製構鏇簾鹽繭鏇鑰積築襯鏇範夢鹹夢鹹願 (膚遞夢選簾鏇鏇襯鬱糧, 膚觸積壓鑰齋積鹽艱憲 ~ 淵構簾繭繭夢積膚繭窪) 更多	-	2018-01-23
				Posterior Tibial Nerve Stimulation (Placebo Plus PTNS)	鑰壓築觸構蓋醖餘製鑰(衊鏇糧遞積獵構廠襯簾) = 膚夢積遞積遞鑰鏇壓選積築襯鏇範夢鹹夢鹹願 (膚遞夢選簾鏇鏇襯鬱糧, 壓膚艱窪繭糧網鏇淵蓋 ~ 齋鹹鹽觸窪鏇鬱鹽壓衊) 更多
NCT03952299 (Pubmed \| J Pediatr Urol) 人工标引	临床3期	膀胱过度活动症	35	Transdermal oxybutynin patch (TOP)	齋築廠簾糧顧廠膚蓋簾(鑰憲醖糧鑰觸獵餘壓艱) = The main side effect was skin irritation at TOP site (35%), leading to discontinuation in 20% 壓獵鹽鹹艱選醖獵襯醖 (鏇鏇顧艱鏇獵製鏇觸獵 )	积极	2014-08-01